

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

CELLECTAR BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

2834

(Primary Standard Industrial Classification Code Number)

04-3321804
(I.R.S. Employer Identification No.)

100 Campus Drive
Florham Park, New Jersey 07932
Telephone (608) 441-8120
(Address, including zip code and telephone number, including area code, of registrant's principal executive offices)

James V. Caruso
President and Chief Executive Officer
100 Campus Drive
Florham Park, New Jersey 07932
Telephone (608) 441-8120

(Name, address, including zip code and telephone number, including area code, of agent for service)

With copies to:

Gregory J. Lynch, Esq.
Joshua B. Erekson, Esq.
Michael Best & Friedrich LLP
One South Pinckney Street, Suite 700
Madison, Wisconsin 53703
(608) 257-3501

Michael F. Nertney
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105-0302
(212) 370-1300

From time to time after the effectiveness of this registration statement.
(Approximate date of commencement of proposed sale to the public)

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. **333-238132**

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered ⁽¹⁾	Proposed Maximum Aggregate Offering Price ^{(1) (2)}	Amount of Registration Fee
Common Stock, par value \$0.00001 per share ⁽³⁾⁽⁴⁾	\$ 2,500,000	\$
Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof	2,500,000	
Warrants to purchase common stock and common stock issuable upon exercise of warrants ⁽⁵⁾	1,750,000	
Total	\$ 4,250,000	\$ 552

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act").

(2) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.

- (3) Represents only the additional number of securities being registered. Does not include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-238132).
- (4) The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is \$2,500,000.
- (5) Includes additional proceeds payable because the exercise price of the warrants will be 105% of the offering price of the common stock.

This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE

This Registration Statement is being filed pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of \$2,500,000 in (i) additional shares of common stock, par value \$0.00001 per share each with one-half of a Series H Warrant to purchase a share of common stock, (ii) additional pre-funded warrants each with one-half of a Series H Warrant to purchase a share of common stock, (iii) shares of common stock issuable upon exercise of the additional pre-funded warrants and (iv) shares of common stock issuable upon exercise of the Series H Warrants. The contents of the Registration Statement on Form S-1 (Registration No. 333-238132), as amended, including the exhibits and power of attorney thereto, which will be declared effective by the Securities and Exchange Commission on June 2, 2020, are incorporated by reference in this Registration Statement.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits.

(a) Exhibits.

The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

EXHIBIT INDEX

Exhibit No.	Description	Incorporated by Reference		
		Form	Filing Date	Exhibit No.
5.1*	Legal Opinion of Michael Best & Friedrich LLP			
23.1*	Consent of Michael Best & Friedrich LLP (included in Exhibit 5.1)			
23.2*	Consent of Baker Tilly Virchow Krause, LLP			

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Florham Park, State of New Jersey, on June 2, 2020.

CELLECTAR BIOSCIENCES, INC.

By: /s/ Dov Elefant
Dov Elefant
Vice President and Chief Financial Officer

Signature	Title	Date
<u>*</u> James V. Caruso	Chief Executive Officer and Director <i>(principal executive officer)</i>	June 2, 2020
<u>/s/ Dov Elefant</u> Dov Elefant	Chief Financial Officer <i>(principal financial officer and principal accounting officer)</i>	June 2, 2020
<u>*</u> Frederick W. Driscoll	Director	June 2, 2020
<u>*</u> Stephen A. Hill	Director	June 2, 2020
<u>*</u> Stefan D. Loren, Ph.D.	Director	June 2, 2020
<u>*</u> John Neis	Director	June 2, 2020
<u>*</u> Douglas J. Swirsky	Director	June 2, 2020

* /s/ Dov Elefant as attorney-in-fact.



June 2, 2020

Collectar Biosciences, Inc.
100 Campus Drive
Florham Park, New Jersey 07932

Re: S-1 Registration Statement

Ladies and Gentlemen:

We have acted as counsel to Collectar Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the registration statement on Form S-1 (File No. 333-238132) filed with the Securities and Exchange Commission (the “Commission”) on May 8, 2020, as amended, and the registration statement filed by the Company with the Commission on June 2, 2020 pursuant to Rule 462(b) (collectively, the “Registration Statement”), relating to the registration under the Securities Act of 1933, as amended (the “Act”), of up to \$2,500,000 in Securities (as defined below), which may (i) shares (the “Common Shares”) of the Company’s common stock, \$0.00001 par value per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) the issuance of the Pre-Funded Warrant Shares upon exercise of the Pre-Funded Warrants, (iv) Series H warrants (the “Series H Warrants”) to purchase shares of Common Stock (the “Series H Warrant Shares”), and (v) the issuance of the Series H Warrant Shares upon exercise of the Series H Warrants. The Common Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, The Series H Warrants and the Series H Warrant Shares are collectively referred to hereunder as the “Securities”).

In connection with this opinion, we have examined and relied upon originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently sought to verify such matters.

In rendering the opinions set forth herein, we have reviewed originals or copies, certified or otherwise identified to our satisfaction, of such other documents, corporate records, instruments, agreements, certificates and public records, and we have made such inquiries of the officers of the Company and have investigated such matters of law as we deemed to be necessary to form a basis for the opinions expressed herein. We have relied upon and assumed: (i) the genuineness of all signatures of persons signing all documents in connection with which this opinion is rendered; (ii) the authenticity of all documents submitted to us as originals; (iii) the conformity to authenticated original documents of all documents presented to us as certified, conformed, telefaxed or reproduced copies (iv) that the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act; (v) that a Prospectus Supplement will have been filed with the Commission describing the Securities offered thereby; (vi) that the Securities will be issued and the Securities will be sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement and the applicable Prospectus Supplement; (vii) that a definitive purchase, underwriting, subscription, placement agency or similar agreement with respect to any Securities offered will have been duly authorized and validly executed and delivered by the Company and the other parties thereto; (viii) that any Securities issuable upon conversion, exchange, redemption or exercise of any Securities being offered will be duly authorized, created and, if appropriate, reserved for issuance upon such conversion, exchange, redemption or exercise; (ix) with respect the Shares and Preferred Shares offered, that there will be sufficient shares of Common Stock or Preferred Stock authorized under the Company’s organizational documents that are not otherwise reserved for issuance; and (x) the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.

Based upon and subject to the foregoing, it is our opinion that:

1. With respect to the Shares to be sold by the Company, when both: (a) the Board of Directors of the Company or a duly constituted and acting committee thereof (such Board of Directors or committee being hereinafter referred to as the "Board") has taken all necessary corporate action to approve the issuance and the terms of the offering of the Shares and related matters; and (b) certificates representing the Shares have been duly executed, countersigned, registered and delivered in accordance with the definitive underwriting agreement approved by the Board upon payment of the consideration therefor (not less than the par value of the Common Stock) provided for therein, then the Shares will be validly issued, fully paid and nonassessable.

2. With respect to the Pre-Funded Warrants, when both: (a) the Board has taken all necessary corporate action to approve the issuance and terms of the Pre-Funded Warrants and related matters; and (b) the Pre-Funded Warrants have been duly executed and delivered against payment therefor, pursuant to the definitive underwriting agreement duly authorized, executed and delivered by the Company, and the certificates for the Pre-Funded Warrants have been duly executed and delivered by the Company, then the Pre-Funded Warrants will be validly issued and will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

3. With respect to the Pre-Funded Warrant Shares, when all necessary actions have been taken by the holder of Pre-Funded Warrants to effect an exercise of the Pre-Funded Warrants to purchase shares of Common Stock, then the Pre-Funded Warrant Shares, including payment of the exercise price therefor, will be validly issued, fully paid and nonassessable.

4. With respect to the Series H Warrants, when both: (a) the Board has taken all necessary corporate action to approve the issuance and terms of the Series H Warrants and related matters; and (b) the Series H Warrants have been duly executed and delivered against payment therefor, pursuant to the definitive underwriting agreement duly authorized, executed and delivered by the Company, and the certificates for the Series H Warrants have been duly executed and delivered by the Company, then the Series H Warrants will be validly issued and will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

5. With respect to the Series H Warrant Shares, when all necessary actions have been taken by the holder of Series H Warrants to effect an exercise of the Series H Warrants to purchase shares of Common Stock, then the Series H Warrant Shares, including payment of the exercise price therefor, will be validly issued, fully paid and nonassessable.

Our opinion that any document is legal, valid and binding is qualified as to:

- a. limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium or other laws relating to or affecting the rights of creditors generally;
- b. rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and
- c. general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief and limitation of rights of acceleration, regardless of whether such enforceability is considered in a proceeding in equity or at law.

We express no opinion as to the laws of any jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware. We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to us under the heading "Legal Matters" in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement. We also consent to the reference to our firm under the heading "Legal Matters" in the Registration Statement. In giving such consent, we do not thereby concede that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

This opinion letter is given as of the date hereof, and we express no opinion as to the effect of subsequent events or changes in law occurring or becoming effective after the date hereof. We assume no obligation to update this opinion letter or otherwise advise you with respect to any facts or circumstances or changes in law that may hereafter occur or come to our attention (even though the change may affect the legal conclusions stated in this opinion letter).

[Signature Page Follows]

Very truly yours,

MICHAEL BEST & FRIEDRICH LLP

/s/ Michael Best & Friedrich LLP



CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Registration Statement Form S-1 filing pursuant to Rule 462(b) of Collectar Biosciences, Inc. and Subsidiary (the "Company") of our report dated March 9, 2020, which includes an explanatory paragraph as to the Company's ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Collectar Biosciences, Inc. and Subsidiary for the years ended December 31, 2019 and 2018 which are incorporated by reference in this Registration Statement. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

BakerTillyVirchowKrause, LLP

Madison, Wisconsin
June 2, 2020
